Takeda Pharmaceutical Company
- Health
Takeda Launches Adynovate To Advance Prophylaxis Treatment For Hemophilia Patients in India
·An extended half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A, resulting in lower weekly infusion rates than standard FVIII,…
Read More » - Business
Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema
Shanghai, China & Osaka, Japan: − TAKHZYRO is the first approved modern therapy for the preventive treatment of hereditary angioedema…
Read More » -
Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific
Osaka, Japan: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of…
Read More »